Vemurafenib/interferon-alpha: Various toxicities.

A study conducted between January 2013 and December 2022 described seven patients with hairy cell leukemia who developed various toxicities while being treated with vemurafenib. These toxicities included photosensitivity, tumorlysis syndrome grade 2, arthralgia, toxicoderma, atrophy of skin, keratoacanthoma, and hyperkeratosis. Additionally, three patients did not respond to treatment with interferon-alpha. The patients initially received interferon alpha, cladribine, or rituximab before starting vemurafenib. The specific details of the treatments, such as routes and duration, were not provided. [Extracted from the article]